Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q3 | Nov 8, 2025 | Summers Value Fund | 20.4% | 4.9% | ADMA, CCSI, DERM, ELMD, INSP, LGND, LQDA, QURE, SPOK, SPRY, UFPT, ZIMV | Biotechnology, healthcare, innovation, M&A, Pharmaceuticals, Regulatory, small cap, value | The fund argues that healthcare, despite facing regulatory uncertainty, budget constraints, and political risk, now presents one of the most attractive investment environments in years. Investor outflows and sentiment deterioration have created mispricings, while fundamentals remain supported by innovation, demographics, and acquisition demand from large pharma. The manager is increasing exposure to biopharma and specialty healthcare names with strong product pipelines and cash-flow potential. | View | |
| 2025 Q3 | Oct 28, 2025 | Baron Discovery Fund | 2.8% | 10.6% | AAON, AEIS, BIRK, BMI, CDNA, CYBR, DKNG, DT, EXAS, GTLS, INSP, KTOS, LLYVA, MEG, MRCY, PAR, PRMB, SPRY, WING, WYNN | cybersecurity, defense, earnings, growth, Quality, small cap, technology, water | The fund lagged amid speculative rallies in small caps but benefited from holdings in defense technology and cybersecurity such as Kratos, Mercury Systems, and Netskope. Managers emphasized discipline in avoiding junk rallies, maintaining focus on companies with sustainable earnings and cash flow. The portfolio is positioned for alpha through high-quality, high-margin growth names benefiting from rising defense budgets and digital security demand. | KTOS WING INSP PAR BIRK KTOS WING INSP BIRK |
View |
| 2025 Q3 | Oct 24, 2025 | NCG SMID Cap Growth Strategy | 7.1% | 4.3% | AAON, ADMA, AEHR, APLD, AVAV, BE, CDNA, FROG, KVYO, LEU, MIRM, MP, PAR, PGY, PI, PL, PRCH, SPRY, STRL, TOL, XMTR | AI, earnings, growth, industrials, infrastructure, Rate Cuts, small caps, technology | SMID caps trailed speculative segments, but the portfolio emphasizes company-specific growth in industrials and diversified technology (software, semis, AI infrastructure). Exposure to basic materials tied to aerospace/industrial demand complements underweights in consumer and health care. The team expects improving earnings breadth as policy support and easing rates work through. | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Aug 8, 2025 | Seeking Alpha | Bret Jensen | ARS Pharmaceuticals, Inc. | Health Care | Biotechnology | Neutral | NASDAQ | — | View Pitch |
| Aug 8, 2025 | Seeking Alpha | Out of Ignorance | ARS Pharmaceuticals, Inc. | Health Care | Biotechnology | Bull | NASDAQ | — | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||